On-Q-ity
CTC Firm On-Q-ity Closes Shop
NEW YORK (GenomeWeb News) – Circulating tumor cell test development firm On-Q-ity has closed its doors, according to a venture capital investor in the firm.
On-Q-ity, a company developing diagnostics that analyze circulating tumor cells to guide treatment strategies for various cancers, announced that its board of directors has appointed Michael Stocum as president and CEO.
CTC Test Firm On-Q-ity Raises $5M, Names New CEO
NEW YORK (GenomeWeb News) – On-Q-ity today announced it has raised $5 million in financing and it has appointed Michael Stocum as the company's president and CEO.
The microfluidic chip, called the On-Q-ity Circulating Cancer Capture and Characterization Chip, or C5, uses both antibody affinity and size to filter CTCs from normal blood. In a study comparing C5 and a chip using antibody affinity alone, On-Q-ity's dual capture chip "greatly improved" capture rate over the comparator.
On-Q-ity Sees CTC Test Value for Pharma Studies, PGx Efforts
In an interview with GenomeWeb Daily News, On-Q-ity CEO Mara Aspinall touted the advantages of the firm's platform and discussed its potential to monitor patients in clinical trials at a level not currently possible.
Nov 17, 2010
Pairings: Nov 17, 2010
Premium
Dec 15, 2009